No abstract is provided for this article.
No abstract is provided for this article.
When implementing the performance‐based Process Safety Management (PSM) Standard (OSHA 1910.119), industry needs to comply with applicable recognized and generally accepted good engineering practices (RAGAGEP) for their facility. While this may seem like a simple task, determining what is applicable and how it affects the design, construction, inspection/testing, and operations, it can be a significant effort. This paper aims to provide guidance on interpreting the “should” versus “shall” debate, particularly how to deal with “should” provisions, why this matters, and share lessons learned from AcuTech's extensive onsite observations where the impacts of these interpretations are seen in process safety programs.
No abstract is provided for this article.
The authors reply: We do not advocate oral monotherapy with artemisinins.Instead, we en-courage the appropriate use of ACTs and fully support global efforts to eliminate malaria.Recent data show that regionally applied treatment and control measures have been highly effective in the Greater Mekong Subregion. 1 Therapy with dihydroartemisinin-piperaquine fails because of resistance to piperaquine 2 and also perhaps because dihydroartemisinin is more prone to decomposition than artesunate. 3 More recent studies of pyronaridine-artesunate, including a study from Vietnam, confirm that cure rates are higher than 95% and reassure us that effective treatments are available. 4 Thus, artemisinins remain the only available drug class that can manage and eliminate P. falciparum if ACTs are appropriately adjusted, as we elaborated in our Perspective article.Furthermore, our global community should acknowledge a shared future in which no country is neglected.Urgent actions to control malaria should be focused on areas where the highest disease burdens are present, such as in Africa, where, for example, Nigeria bears 25% of the world's malaria burden. 5
No abstract is provided for this article.
No abstract is provided for this article.
KAE609 (cipargamin; formerly NITD609, Novartis Institute for Tropical Diseases) is a new synthetic antimalarial spiroindolone analogue with potent, dose-dependent antimalarial activity against asexual and sexual stages of Plasmodium falciparum.